These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 1687612)
41. An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Wilens TE; Morrison NR; Prince J Expert Rev Neurother; 2011 Oct; 11(10):1443-65. PubMed ID: 21955201 [TBL] [Abstract][Full Text] [Related]
42. Using psychoactive medication to intervene in children's behaviour: an evidence-based practice? Parsonson BS J Prim Health Care; 2009 Mar; 1(1):6-10. PubMed ID: 20690480 [No Abstract] [Full Text] [Related]
43. Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder. Cyr M; Brown CS Drugs; 1998 Aug; 56(2):215-23. PubMed ID: 9711446 [TBL] [Abstract][Full Text] [Related]
44. Antidepressants in the treatment of attention-deficit/hyperactivity disorder. Popper CW J Clin Psychiatry; 1997; 58 Suppl 14():14-29; discussion 30-1. PubMed ID: 9418743 [TBL] [Abstract][Full Text] [Related]
46. The neuropharmacology of attention-deficit hyperactivity disorder. Zametkin AJ; Borcherding BG Annu Rev Med; 1989; 40():447-51. PubMed ID: 2567145 [TBL] [Abstract][Full Text] [Related]
47. Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation. Ornoy A Pharm Res; 2018 Feb; 35(3):46. PubMed ID: 29411149 [TBL] [Abstract][Full Text] [Related]
48. Risks and benefits of drugs used in the management of the hyperactive child. Fox AM; Rieder MJ Drug Saf; 1993 Jul; 9(1):38-50. PubMed ID: 8347290 [TBL] [Abstract][Full Text] [Related]
49. Novel Phenethylamines and Their Potential Interactions With Prescription Drugs: A Systematic Critical Review. Inan F; Brunt TM; Contrucci RR; Hondebrink L; Franssen EJF Ther Drug Monit; 2020 Apr; 42(2):271-281. PubMed ID: 32022784 [TBL] [Abstract][Full Text] [Related]
51. Age-related considerations in the treatment of ADHD. Newcorn JH CNS Spectr; 2007 Dec; 12(12 Suppl 23):10-3. PubMed ID: 18396511 [No Abstract] [Full Text] [Related]
52. Algorithms for the treatment of affective illness, primary disorder of vigilance, and task-dependent attention disorders (learning disabilities) in children and adolescents. Weinberg WA; Schraufnagel CD; Harper CR; Brumback RA J Child Neurol; 1996 May; 11(3):220-7. PubMed ID: 8734027 [No Abstract] [Full Text] [Related]
53. Child Psychotherapy, Child Analysis, and Medication: A Flexible, Integrative Approach. Whitman L Psychoanal Study Child; 2015; 69():394-415. PubMed ID: 27337826 [TBL] [Abstract][Full Text] [Related]
54. Cognitive effects of psychostimulant medication in hyperactive children. Everett J; Thomas J; Cote F; Levesque J; Michaud D Child Psychiatry Hum Dev; 1991; 22(2):79-87. PubMed ID: 1686856 [TBL] [Abstract][Full Text] [Related]
55. Fluoxetine for ADHD in a young child. Campbell NB; Tamburrino MB; Evans CL; Franco KN J Am Acad Child Adolesc Psychiatry; 1995 Oct; 34(10):1259-60. PubMed ID: 7592260 [No Abstract] [Full Text] [Related]
56. Psychostimulants, antidepressants and neurokinin-1 receptor antagonists ('motor disinhibitors') have overlapping, but distinct, effects on monoamine transmission: the involvement of L-type Ca2+ channels and implications for the treatment of ADHD. Stanford SC Neuropharmacology; 2014 Dec; 87():9-18. PubMed ID: 24727210 [TBL] [Abstract][Full Text] [Related]
57. [Diagnosis and drug treatment in hyperactive children]. Hara H No To Hattatsu; 1994 Mar; 26(2):169-74. PubMed ID: 8136193 [TBL] [Abstract][Full Text] [Related]
58. Pemoline hepatotoxicity in children. Marotta PJ; Roberts EA J Pediatr; 1998 May; 132(5):894-7. PubMed ID: 9602211 [TBL] [Abstract][Full Text] [Related]
59. Relative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity disorder. Safer DJ J Child Adolesc Psychopharmacol; 1992; 2(4):279-90. PubMed ID: 19630610 [TBL] [Abstract][Full Text] [Related]